Federal Register / Vol. 89, No. 11 / Wednesday, January 17, 2024 / Notices 2963 

guidelines may be formally referenced 

as ‘‘the poverty guidelines updated 

periodically in the Federal Register by 

the U.S. Department of Health and 

Human Services under the authority of 

42 U.S.C. 9902(2).’’ 

Some federal programs use a 

percentage multiple of the guidelines 

(for example, 125 percent or 185 percent 

of the guidelines), as noted in relevant 

authorizing legislation or program 

regulations. Non-Federal organizations 

that use the poverty guidelines under 

their own authority in non-federallyfunded activities also may choose to use 

a percentage multiple of the guidelines. 

The poverty guidelines do not make a 

distinction between farm and non-farm 

families, or between aged and non-aged 

units. (Only the Census Bureau poverty 

thresholds have separate figures for aged 

and non-aged one-person and twoperson units.) 

This notice does not provide 

definitions of such terms as ‘‘income’’ or 

‘‘family’’ as there is considerable 

variation of these terms among programs 

that use the poverty guidelines. The 

legislation or regulations governing each 

program define these terms and 

determine how the program applies the 

poverty guidelines. In cases where 

legislation or regulations do not 

establish these definitions, the entity 

that administers or funds the program is 

responsible to define such terms as 

‘‘income’’ and ‘‘family.’’ Therefore, 

questions such as net or gross income, 

counted or excluded income, or 

household size should be directed to the 

entity that administers or funds the 

program. 

Dated: January 11, 2024. 

Xavier Becerra, 

Secretary, Department of Health and Human 

Services. 

[FR Doc. 2024–00796 Filed 1–16–24; 8:45 am] 

BILLING CODE 4150–05–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Interagency Coordinating Committee 

on the Validation of Alternative 

Methods Communities of Practice 

Webinar on Implementing 

Computational Approaches for 

Regulatory Safety Assessments; 

Notice of Public Webinar; Registration 

Information 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Interagency Coordinating 

Committee on the Validation of 

Alternative Methods (ICCVAM) 

announces the public webinar 

‘‘Implementing Computational 

Approaches for Regulatory Safety 

Assessments.’’ The webinar is organized 

on behalf of ICCVAM by the National 

Toxicology Program Interagency Center 

for the Evaluation of Alternative 

Toxicological Methods (NICEATM). 

Interested persons may participate via 

the web meeting platform. Time will be 

allotted for questions from the audience. 

Information about the webinar and 

registration are available at https://

ntp.niehs.nih.gov/go/commprac-2024. 

DATES: 

Webinar: January 29, 2024, 10 a.m. to 

approximately 12 noon EST. 

Registration for Webinar: January 10, 

2024, until 12:00 noon EST January 29, 

2024. Registration to view the webinar 

is required. 

ADDRESSES: Webinar web page: https:// 

ntp.niehs.nih.gov/go/commprac-2024. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Helena Hogberg, Staff Scientist, 

NICEATM, email: helena.hogbergdurdock@nih.gov, telephone: (984) 287– 

3150. 

SUPPLEMENTARY INFORMATION: 

Background: ICCVAM promotes the 

development and validation of toxicity 

testing methods that protect human 

health and the environment while 

replacing, reducing, or refining animal 

use. ICCVAM also provides guidance to 

test method developers and facilitates 

collaborations that promote the 

development of new test methods. To 

address these goals, ICCVAM will hold 

a Communities of Practice webinar on 

‘‘Implementing Computational 

Approaches for Regulatory Safety 

Assessments.’’ 

Computational toxicology methods 

can be useful for generating bioactivity 

predictions for chemicals for which 

limited toxicity data are available. They 

can also help users understand and 

interpret large, diverse bioactivity data 

sets, or predict how a chemical might 

behave in the body. However, users 

with limited experience with such 

methods may find it difficult to use 

them or interpret their outputs, or even 

understand how the methods could be 

applied in a specific context. 

This webinar will discuss how to 

establish confidence in computational 

approaches for regulatory applications. 

Ongoing activities and key insights will 

be described in three presentations by 

speakers from the U.S. government and 

the private sector focusing on 

applications of tools such as structurebased models to predict chemical 

bioactivity and pharmacokinetic models 

to support understanding of chemical 

metabolism and disposition. The 

preliminary agenda and additional 

information about presentations will be 

posted at https://ntp.niehs.nih.gov/go/ 

commprac-2024 as they become 

available. 

Webinar and Registration: This 

webinar is open to the public with time 

scheduled for questions by participants 

following each presentation. 

Registration for the webinar is required. 

Registration will open on or before 

January 10, 2024, and remain open 

through 12 noon EST on January 29, 

2024. Registration is available at https:// 

ntp.niehs.nih.gov/go/commprac-2024. 

Interested individuals are encouraged to 

visit this web page to stay abreast of the 

most current webinar information. 

Registrants will receive instructions on 

how to access and participate in the 

webinar in the email confirming their 

registration. TTY users should contact 

the Federal TTY Relay Service at 800– 

877–8339. Requests should be made at 

least five business days in advance of 

the event. 

Background Information on ICCVAM 

and NICEATM: ICCVAM is an 

interagency committee composed of 

representatives from 17 Federal 

regulatory and research agencies that 

require, use, generate, or disseminate 

toxicological and safety testing 

information. ICCVAM conducts 

technical evaluations of new, revised, 

and alternative safety testing methods 

and integrated testing strategies with 

regulatory applicability. ICCVAM also 

promotes the scientific validation and 

regulatory acceptance of testing 

methods that more accurately assess the 

safety and hazards of chemicals and 

products and replace, reduce, or refine 

animal use. 

The ICCVAM Authorization Act of 

2000 (42 U.S.C. 285l–3) establishes 

ICCVAM as a permanent interagency 

committee of the National Institute of 

Environmental Health Sciences and 

provides the authority for ICCVAM 

involvement in activities relevant to the 

development of alternative test 

methods. Additional information about 

ICCVAM can be found at https://

ntp.niehs.nih.gov/go/iccvam. 

NICEATM administers ICCVAM, 

provides support for ICCVAM-related 

activities, and conducts and publishes 

analyses and evaluations of data from 

new, revised, and alternative testing 

approaches. NICEATM and ICCVAM 

work collaboratively to evaluate new 

and improved testing approaches 

applicable to the needs of U.S. Federal 

agencies. NICEATM and ICCVAM 

welcome the public nomination of new, 


lotter on DSK11XQN23PROD with NOTICES1
2964 Federal Register / Vol. 89, No. 11 / Wednesday, January 17, 2024 / Notices 

revised, and alternative test methods 

and strategies for validation studies and 

technical evaluations. Additional 

information about NICEATM can be 

found at https://ntp.niehs.nih.gov/go/ 

niceatm. 

Dated: January 10, 2024. 

Richard P. Woychik, 

Director, National Institute of Environmental 

Health Sciences and National Toxicology 

Program, National Institutes of Health. 

[FR Doc. 2024–00758 Filed 1–16–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NINDS R35 Overflow 

Meeting. 

Date: January 19, 2024. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Contact Person: DeAnna Lynn Adkins, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Activities, NINDS/NIH NSC, 6001 Executive 

Blvd., Rockville, MD 20852, 301–496–9223, 

deanna.adkins@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS.) 

Dated: January 11, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00794 Filed 1–16–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications/ 

contract proposals and the discussions 

could disclose confidential trade secrets 

or commercial property such as 

patentable material, and personal 

information concerning individuals 

associated with the grant applications/ 

contract proposals, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel TEP–8: 

SBIR Contract Review. 

Date: February 14, 2024. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W254, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Susan Lynn Spence, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W254, Rockville, Maryland 

20850, 240–620–0819, susan.spence@

nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; TEP–6A: 

SBIR Contract Review. 

Date: February 22–23, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W254, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Susan Lynn Spence, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W254, Rockville, Maryland 

20850, 240–620–0819, susan.spence@

nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Human 

Tumor Atlas (HTA) Research Centers (U01). 

Date: February 29, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W240, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Hasan Siddiqui, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W240, Rockville, 

Maryland 20850, 240–276–5122, 

hasan.siddiqui@nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; TEP–6B: 

SBIR Contract Review. 

Date: March 1, 2024. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W254, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Susan Lynn Spence, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W254, Rockville, Maryland 

20850, 240–620–0819, susan.spence@

nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP 11: 

NCI Clinical and Translational Cancer 

Research. 

Date: March 7, 2024. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W602, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Delia Tang, M.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W602, Rockville, Maryland 20850, 

240–276–6456, tangd@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Translational Research Toward Development 

of a Kaposi Sarcoma Herpesvirus (KSHV) 

Vaccine (U01). 

Date: March 12, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W264, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Ombretta Salvucci, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W264, Rockville, 

Maryland 20850, 240–276–7286, salvucco@

mail.nih.gov. 


lotter on DSK11XQN23PROD with NOTICES1